Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

<label id="y1jih"><i id="y1jih"></i></label>

<del id="y1jih"></del><legend id="y1jih"><strike id="y1jih"><var id="y1jih"></var></strike></legend>

<form id="y1jih"></form>

<li id="y1jih"><table id="y1jih"></table></li>

You are here: Industry Insights > Market News > Janssen's Stelara shows promise across two dosages in ulcerative colitis

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Kojic Acid Dipalmitate Powder

Kojic Acid Dipalmitate Powder

Psoralea Corylifolia Extract Bakuchiol Oil 98%

Psoralea Corylifolia Extract Bakuchiol Oil 98%

Natural Preservative Nisin E234 Powder

Natural Preservative Nisin E234 Powder

Betaine Anhydrous Powder

Betaine Anhydrous Powder

Palmitoylethanolamide (PEA) Powder

Palmitoylethanolamide (PEA) Powder

BIONOON FREEZON 28T

BIONOON FREEZON 28T

Janssen's Stelara shows promise across two dosages in ulcerative colitis

pharmafileNovember 20, 2018

Tag: Janssen , Stelara , IBDQ

Favorites

Previous:Menlo Therapeutics' cough drug fails to meet primary endpoint in phase II trial

Next:New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs

Related News

From Molecule to Market: Innovations Accelerating the Future of Drug Development

Annie RoysSeptember 04, 2025

Drug discovery and development has historically been a lengthy, high risk, and costly process, often spanning more than a decade and consuming billions of dollars before a product reaches patients.

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

PRNewswireAugust 21, 2025

Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning

PRNewswireAugust 20, 2025

Janssen's Stelara shows promise across two dosages in ulcerative colitis | Pharmasources.com

NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals

Biotech NewswireAugust 20, 2025

Neurizon? Therapeutics Limited is pleased to report positive topline results from the Open-Label Extension study of its lead candidate NUZ-001, for the treatment of amyotrophic lateral sclerosis , the major form of motor neurone disease.

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM

LINCOMYCIN HCL

GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides

CEFALEXINE cephalosporins

CEFALEXINE cephalosporins

CEFRADINE cephalosporins

CEFRADINE cephalosporins

CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

CEFIXIME cephalosporins

CEFIXIME cephalosporins

CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins

CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號(hào)-182 滬公網(wǎng)安備31010402010101號(hào)
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight July 2025

PharmaSources Customer Service

<td id="y8cpd"></td>

<address id="y8cpd"><menuitem id="y8cpd"></menuitem></address>